Nurix Therapeutics, Inc. (NRIX) Stock

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. is led by CEO Arthur T. Sands, employs 286 people, headquartered in US, publicly traded since 2020.

Nurix Therapeutics, Inc. (NRIX) stock trades at $25.34 with a market capitalization of $2.77B. The stock is valued at a negative price-to-earnings (P/E) ratio of -6.61, reflecting a net loss over the last twelve months, price-to-book of 6.29, price-to-sales of 64.36. Over the past 52 weeks the stock has ranged between $9.00 and $28.23, and currently trades 10.2% below its 52-week high.

On profitability, Nurix Therapeutics, Inc. generates a return on equity (ROE) of -76.09% (negative, reflecting a net loss), return on capital employed of -77.92%, an operating margin of -4.39%, a net profit margin of -928.44%.

Nurix Therapeutics, Inc. by the numbers, 2018–2025

Between 2018 and 2025 Nurix Therapeutics, Inc. reported revenue of $37.0M rising to $84.0M, a change of +127.0% across 8 years. Compounded, revenue has grown 36.1% a year over five years, 29.1% over three, 52.7% over the last twelve months. Net profit fell to $-264.0M.

Operating margin went from -26.0% in 2018 to -340.2% in 2025, a fall of 314.2 percentage points. The most recent net margin is -928.44%. On a trailing twelve-month basis to Jun '26, revenue is $37.0M and net profit $-341.0M.

Borrowings stand at $56.0M, cash from operations was $-249.0M in the latest year, positive in 1 of the last 8.

Return on equity has averaged -50.2% over five years, and was -49.0% in the most recent year.

The share price itself has compounded at -11.0% a year over five years, 16.4% over three, 44.0% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Nurix Therapeutics, Inc. (NRIX) — frequently asked questions